Portal de investigación
OBSERVATIONAL EPIDEMIOLOGICAL STUDY OF CANCER-ASSOCIATED THROMBOSIS: REGISTRY OF THROMBOSIS & N E OPLASIA OF SEO M (TESEO STUDY).
Datos básicos
- Protocolo:
- SEO-ANT-2017-01
- EUDRACT:
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Año de incio:
- 2018
- Año de finalización:
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma (Dec, 10.1007/s11060-023-04513-1, 2023)
Gately L; (...); Balana C
Correction. 10.1007/s11060-024-04581-x. 2024
A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.
Gately, L.; (...); Balana, C.
Article. 10.1007/s11060-023-04513-1. 2023
A COMBINED ANALYSIS OF TWO RANDOMISED STUDIES EXPLORING THE IMPACT OF EXTENDED POST-RADIATION TEMOZOLOMIDE ON SURVIVAL OUTCOMES IN NEWLY DIAGNOSED GLIOBLASTOMA
Gately, Lucy; (...); Balana, Carmen
Meeting Abstract. 2023
A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study.
Martínez-Trufero J; (...); Gutiérrez A
Article. 10.3390/cancers13040792. 2021
A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)
Capdevila, J; (...); Manzano, JL
Meeting Abstract. 10.1016/j.annonc.2020.08.1373. 2020
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01).
Balana C; (...); Carrato C
Article. 10.1093/neuonc/noaa107. 2020
Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group.
Battisti NML; (...); Wildiers H
Review. 10.1016/j.jgo.2020.07.008. 2020
Addressing the challenges of cancer care in older adults: The unique benefits of oncogeriatric evaluation and management.
Martinez-Peromingo, Javier; (...); Girones, Regina
Letter. 10.1016/j.regg.2023.03.002. 2023
Advances in Transversal Topics Applicable to the Care of Bladder Cancer Patients in the Real-World Setting
Garrido Siles, Marga; (...); Angel Climent, Miguel
Review. 10.3390/cancers14163968. 2022
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial.
Garcia-Del-Muro, Xavier; (...); Alemany, Ramon
Article. 10.1158/1078-0432.CCR-24-2636. 2025
Cancer worry at higher-risk sample of hereditary cancer in Spain.
Costa-Requena G, Richart-Aznar P, Segura-Huerta Á
Article. 10.1097/CEJ.0000000000000862. 2024
CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study
Frezza, Anna Maria; (...); Gronchi, Alessandro
Article. 10.1002/cam4.5015. 2022
Clinical Characteristics and Management of Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: A Feasibility Analysis of Electronic Health Records Using Natural Language Processing.
Ortiz A; (...); Rodriguez M
Article. 10.1159/000528784. 2023
CNL and aCML should be considered as single entity based on molecular profiles and outcomes.
Carreño-Tarragona G; (...); Cross, Nicholas C. P.
Article. 10.1182/bloodadvances.2022008204. 2022
Comparison of psychological distress for breast, ovarian and colorectal cancer predisposition in a Spanish sample at high risk of hereditary cancer.
Costa-Requena, Gema; (...); Segura-Huerta, Angel
Article. 10.1097/CEJ.0000000000000734. 2022
Consensus on strategies in the management of opioid-induced constipation in cancer patients
Sarrio, RG; (...); Sales, JP
Meeting Abstract. 2019
Co-occurrence of germline pathogenic variants for different hereditary cancer syndromes in patients with Lynch syndrome.
Ferrer-Avargues R; (...); Soto JL
Article. 10.1002/cac2.12134. 2021
Correction: Update on the management of elderly patients with colorectal cancer.
Soler-González G; (...); Gironés-Sarrió R
Correction. 10.1007/s12094-023-03351-x. 2024
COVID-19 and hospitalised cancer patients: Now it's time for patients to talk
Arrue, BD; (...); Sarrio, RG
Meeting Abstract. 10.1016/j.annonc.2020.08.2061. 2020
Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first-line anti-programmed death-1 monotherapy: A real-world multicentre observational cohort study.
Ochenduszko, Sebastian; (...); Maiques, Inmaculada Maestu
Article. 10.1111/pcmr.13093. 2023
Characterization of thrombosis risk in patients with cancer
Cerezuela, P; (...); Trujillo-Santos, J
Meeting Abstract. 10.1016/j.thromres.2018.02.121. 2018
Delphi consensus on strategies in the management of opioid-induced constipation in cancer patients
Sarrio, RG; (...); Porta-Sales, J
Article. 10.1186/s12904-020-00693-z. 2021
Development and validation of an early death risk score for older patients treated with chemotherapy for cancer.
Batlle, JF; (...); Molina-Garrido, MJ
Meeting Abstract. 2020
Development and Validation of an Early Mortality Risk Score for Older Patients Treated with Chemotherapy for Cancer
Feliu, J; (...); Molina-Garrido, MJ
Article. 10.3390/jcm10081615. 2021
Diagnostic demographics of radioiodine-refractory differentiated thyroid cancer (RR-DTC) and usage patterns of local and systemic therapies (ERUDIT study)
Lopez, C; (...); Rodriguez-Villanueva, J
Meeting Abstract. 10.1016/j.annonc.2020.08.1412. 2020
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin.
Capdevila, J.; (...); Manzano, J. L.
Article. 10.1038/s41467-023-38611-5. 2023
Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations
Salvador-Coloma, C; (...); Juan, O
Article. 10.21037/jtd.2018.02.30. 2018
Elderly glioblastoma patients: Survival analysis according adjuvant therapy and tumor molecular analysis.
Angeles Vaz, Maria; (...); De Las Penas Bataller, Ramon
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.e14046. 2021
Encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma, real-world evidence in Spain (GEM 2002-BECARE)
Soria, A.; (...); Cerezuela-Fuentes, P.
Meeting Abstract. 10.1016/j.annonc.2023.09.2248. 2023
Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study).
Marquez-Rodas, Ivan; (...); Berrocal, Alfonso
Article. 10.1093/neuonc/noae116. 2024
Experience of GEINO (Spanish cooperative group for research in neuro-oncology) oncologists in the management of adult medulloblastoma
Villar, MV; (...); Santos, JD
Meeting Abstract. 10.1016/j.annonc.2021.08.008. 2021
Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer.
Nadal E; (...); Gironés R
Article. 10.1007/s12094-023-03286-3. 2023
Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer.
Torregrosa-Maicas MD; (...); Gironés-Sarrió R
Article. 10.1007/s12094-021-02766-8. 2022
Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM).
Gately L; (...); Balana C
Article. 10.1007/s11060-024-04668-5. 2024
EXTENDING ADJUVANT TEMOZOLOMIDE LONGER THAN SIX CYCLES DOESN'T ADD ANY BENEFIT TO GLIOBLASTOMA PATIENTS ACCORDING TO THE RANDOMIZED GEINO-014 TRIAL
Balana, C.; (...); Del Barco, S.
Meeting Abstract. 10.1093/neuonc/noz126.293. 2019
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study
Jimenez-Fonseca, Paula; (...); Garcia-Carbonero, Rocio
Article. 10.1159/000514808. 2021
Final database lock results of the phase 2 cohort of lenvatinib plus pembrolizumab for progressive disease after a PD-1/PD-L1-containing therapy in metastatic clear cell renal cell carcinoma
Lee, Chung-Han; (...); Motzer, Robert J.
Meeting Abstract. 2023
First in human trial of CEB-01 for retroperitoneal soft tissue sarcoma
Gonzalez, J. A.; (...); Lopez Pousa, A.
Meeting Abstract. 10.1016/j.annonc.2023.09.1161. 2023
First-in-human CEB-01: Novel loco-regional SN-38 release membrane to prevent local recurrence in retroperitoneal sarcomas
Gonzalez-Lopez, Jose Antonio; (...); Pousa, Antonio Lopez
Meeting Abstract. https://doi.org/10.1016/j.annonc.2023.09.1161. 2024
Glasdegib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II GEINO 1602 trial
Vaz, M. A.; (...); Girones, R.
Meeting Abstract. 10.1016/j.annonc.2023.09.1695. 2023
Identification Of Actionable Genetic Targets In Primary Cardiac Sarcomas
Salvador-Coloma, C; (...); de Mora, JF
Article. 10.2147/OTT.S214319. 2019
ImmunoSarc2: A Spanish Sarcoma Group (GEIS) phase Ib trial of doxorubicin and dacarbazine plus nivolumab in first line treatment of advanced leiomyosarcoma
Martin Broto, Javier; (...); Hindi, Nadia
Meeting Abstract. 2023
Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: a multicenter prospective study.
Rondan, Maria Arnal; (...); Sarrio, Regina Girones
Article. 10.1007/s12094-024-03657-4. 2024
Impact of surgery versus other treatment options in recurrent glioblastoma. Analysis of the Spanish Group of Neurooncology Research (GEINO) RETSINE database.
Vaz Salgado, Maria Angeles; (...); De Las Penas Bataller, Ramon
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.e14047. 2021
Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer
Zugazagoitia, J; (...); Manzano, A
Letter. 10.1183/13993003.02431-2017. 2018
Initial Clinical and Treatment Patterns of Advanced Differentiated Thyroid Cancer. ERUDIT Study.
Vallejo Casas, Juan Antonio; (...); Orcajo-Rincon, Lorenzo
Article. 10.1530/ETJ-21-0111. 2022
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial.
Gonzalez-Cao M; (...); Berrocal A
Article. 10.1038/s41467-021-26572-6. 2021
Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trial
Marquez-Rodas, I; (...); Berrocal, A
Meeting Abstract. 10.1016/j.annonc.2021.08.1423. 2021
Lanreotide 120 mg every 28 days (LAN) in patients with locally advanced or metastatic pancreatic neuroendocrine tumors (panNET) in routine clinical practice in Iberia
Alonso-Gordoa, T.; (...); de La Cruz, G.
Meeting Abstract. 2022
Leave no one behind: A global survey of the current state of geriatric oncology practice by SIOG national representatives.
Mizutani, Tomonori; (...); Kanesvaran, Ravindran
Article. 10.1016/j.jgo.2024.101709. 2024
Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146.
Lee, Chung-Han; (...); Motzer, Robert J
Letter. 10.1016/j.eururo.2024.05.003. 2024
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
Lee, CH; (...); Motzer, JR
Article. 10.1016/S1470-2045(21)00241-2. 2021
Long-Term Survival for Brain-Only Oligometastatic NSCLC Patients Treated with Ablative Therapy (AT): Prognostic Factors
Salvador Coloma, C.; (...); Juan-Vidal, O.
Meeting Abstract. 2018
Lymphoscintigraphic findings in patients with lipedema
Forner-Cordero, I; (...); Munoz-Langa, J
Article. 10.1016/j.remn.2018.06.008. 2018
MOLTHY project (TTCC-2020-02): A Spanish observational study for MOLecular characterization of THYroid carcinoma
Baste Rotllan, N.; (...); Mesia, R.
Meeting Abstract. 10.1016/j.annonc.2023.09.999. 2023
Multicenter real-world data of treatment with NALIRI plus 5FU/LV in advanced Spanish pancreatic cancer
Alvarez Gallego, R.; (...); Cubillo, A.
Meeting Abstract. 10.1016/j.annonc.2023.04.238. 2023
Multi-parametric MR Imaging Biomarkers Associated to Clinical Outcomes in Gliomas: A Systematic Review.
Oltra-Sastre M; (...); Garcia-Gomez JM
Article. 10.2174/1573405615666190109100503. 2019
Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG).
Gronchi, Alessandro; (...); Casali, Paolo Giovanni
Article. 10.1200/JCO.23.00908. 2024
Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.
Pasquali, Sandro; (...); Gronchi, Alessandro
Article. 10.1002/cncr.33895. 2022
Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Results of the expanded cohort of myxoid liposarcoma of the randomized clinical trial from the Italian Sarcoma Group (ISG), the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG).
Gronchi, Alessandro; (...); Casali, Paolo Giovanni
Meeting Abstract. 2022
P25.03.B RWD OF IDH MUTANT GLIOMAS IN SPAIN, A RETSINE - GEINO STUDY
Mazariegos, M.; (...); Pineda, E.
Meeting Abstract. 10.1093/neuonc/noae144.446. 2024
Pancreatic cancer, Radiomics and Artificial Intelligence: A Review.
Marti-Bonmati L; (...); Alberich-Bayarri A
Article. 10.1259/bjr.20220072. 2022
Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group.
Aparicio, J.; (...); Germa, J. R.
Article. 10.1007/s12094-020-02393-9. 2021
Peptide Receptor Radionuclide Therapy with [(177)Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions.
del Olmo-Garcia, Maria I.; (...); Merino-Torres, Juan F.
Article. 10.3390/cancers14030584. 2022
Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol
Salazar, Juliana; (...); Sebio, Ana
Article. 10.3390/pharmaceutics16121585. 2024
Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS).
Martin-Broto J; (...); Hindi N
Article. 10.1200/JCO.24.00358. 2024
Phase II trial evaluating olaparib maintenance in patients with metastatic castration resistant prostate cancer (mCRPC) after docetaxel treatment, reaching partial or stable response: SOGUG-IMANOL study.
Juan Fita, Maria Jose; (...); Heras, Lucia
Meeting Abstract. 2023
Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study.
Juan Fita, Maria Jose; (...); Angel Climent, Miguel
Article. 10.3390/cancers15215223. 2023
Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial.
Garcia del Muro, Xavier; (...); Vigues, Francesc
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.4505. 2021
Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy as bladder-sparing therapy in patients with localized muscle invasive bladder cancer: A SOGUG study.
Cuellar, M. Andres; (...); Garcia del Muro, Xavier
Meeting Abstract. 2020
Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC).
Lee, CH; (...); Motzer, RJ
Meeting Abstract. 2020
Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analyses
Lee, CH; (...); Motzer, RJ
Meeting Abstract. 10.1016/j.annonc.2020.08.782. 2020
Phase II trial of palbociclib in advanced sarcoma overexpressing CDK4 gene excluding dedifferentiated liposarcoma (DD LPS): A study from the Spanish Group for Research on Sarcoma (GEIS).
Broto, Javier Martin; (...); Hindi, Nadia
Meeting Abstract. 2022
Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain.
Ortuzar, Ariana; (...); Osorio, Santiago
Article. 10.1007/s00277-022-05044-x. 2022
Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS).
Benavent M; (...); Gallego J
Article. 10.1186/s12955-021-01688-x. 2021
Pilot study of cabozantinib efficacy, safety and tolerability in metastatic renal carcinoma in aged fragile patients
Duran, MAC; (...); Nunez, NF
Meeting Abstract. 10.1016/j.annonc.2020.08.2074. 2020
Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients
Garde-Noguera, J; (...); Juan-Vidal, O
Article. 10.1007/s12094-017-1829-5. 2018
Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients (vol 20, pg 1072, 2018)
Garde-Noguera, J; (...); Juan-Vidal, O
Correction. 10.1007/s12094-018-1916-2. 2018
Predictive factors of grade 3-5 toxicity in older patients with cancer treated with chemotherapy: A prospective multicenter study.
Feliu Batlle, Jaime; (...); Molina-Garrido, Mj
Meeting Abstract. 2019
Prevalence and Clinicopathological Characteristics of Moderate and High-Penetrance Genes in Non-BRCA1/2 Breast Cancer High-Risk Spanish Families
Fonfria, M; (...); Martinez-Duenas, E
Article. 10.3390/jpm11060548. 2021
Prognostic factors in oligometastatic non-small-cell lung cancer (OM-NSCLC)
Juan, O; (...); Codina, JG
Meeting Abstract. 10.1016/S1556-0864(18)30411-8. 2018
Prognostic factors in oligometastatic non-small-cell lung cancer (OM-NSCLC) patients treated with ablative therapy.
Antonio Mendez, Juan; (...); Juan Vidal, Oscar
Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.e21089. 2018
Prognostic role of geriatric assessment (GA) in patients with metastatic prostate cancer (MPCaP) attended in medical oncology.
Girones, Regina, Arnal, Maria, Forcano, Silvia
Meeting Abstract. 2023
Psychiatric symptoms in a Spanish sample with hereditary cancer risk.
Costa-Requena G; (...); Segura-Huerta Á
Article. 10.1007/s12687-022-00580-5. 2022
Real-world clinical practice patterns and outcomes for advanced ovarian cancer in Spain (GEICO-42-R study)
Redondo, Andres; (...); Gonzalez-Martin, Antonio
Article. 10.31083/j.ejgo4206163. 2021
Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and folinic acid in pancreatic ductal adenocarcinoma in Spain
Alvarez-Gallego, Rafael; (...); Cubillo, Antonio
Article. 10.1177/17588359241309828. 2025
Real-world study on characteristics of advanced melanoma patients with sustained complete response (CR) after elective 1st line anti-programmed death-1 (anti-PD1) monotherapy discontinuation.
Ochenduszko, Sebastian; (...); Maestu, Inmaculada
Meeting Abstract. 2022
Redefining radiologic responses (RR) in solid tumors: Shall we brace ourselves for a post-RECIST era? Results from a randomized clinical trial (RCT) on neoadjuvant chemotherapy in high-risk soft-tissue sarcomas (HR-STS) of the trunk or extremities
Vanzulli, Andrea; (...); Gronchi, Alessandro
Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.11553. 2024
Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial.
Vanzulli, A; (...); Gronchi, A
Article. 10.1016/j.esmoop.2025.104299. 2025
Results of phase II randomized study of intermittent versus continuous schedule of vemurafenib plus cobimetinib in BRAF-mutated advanced melanoma.
Gonzalez-Cao, Maria; (...); Berrocal, Alfonso
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.9528. 2021
Risk assessment in brain-only oligometastatic non-small cell lung cancer (BOO-NSCLC) patients (pts): Recursive partioning analysis (RPA) model modification
Salvador Coloma, C.; (...); Juan-Vidal, O.
Meeting Abstract. 2018
RT after Encorafenib and Binimetinib on BRAF mutated melanoma brain metastases. GEM1802-Phase II
Alvarez, A.; (...); Marquez Rodas, I.
Meeting Abstract. 2023
Safety and efficacy of glasdegib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II GEINO 1602 trial
Vaz, Maria Angeles; (...); Martinez-Garcia, Maria
Meeting Abstract. 2022
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.
Gounder, Mrinal M.; (...); Attia, Steven
Article. 10.1200/JCO.21.01829. 2022
SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021).
Martínez-García M; (...); Manuel Sepúlveda-Sánchez J
Article. 10.1007/s12094-022-02803-0. 2022
SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022).
Segura, Pedro Perez; (...); Losada, Estela Pineda
Article. 10.1007/s12094-023-03245-y. 2023
SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022).
Castillón JC; (...); Plazas JG
Article. 10.1007/s12094-023-03205-6. 2023
SIOG COVID-19 Working Group recommendations on COVID-19 therapeutic approaches in older adults with cancer.
Russo, Chiara; (...); Battisti NML
Article. 10.1016/j.jgo.2023.101564. 2023
SOGUG-AVELUMAB_RWD: Comprehensive analysis of real-word data to evaluate the effectiveness and safety of avelumab maintenance therapy in patients with stage IV urothelial carcinoma conducted in Spain.
Juan Fita, Maria Jose; (...); Molina Diaz, Aurea
Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.e1656. 2024
Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapy.
Pasquali, Sandro; (...); Gronchi, Alessandro
Article. 10.1016/j.ebiom.2024.105220. 2024
State of the scientific evidence and recommendations for the management of older patients with gastric cancer.
Paredero-Perez, Irene; (...); Girones-Sarrio, Regina
Article. 10.1016/j.jgo.2023.101657. 2023
Strategies to enhance management of HER2-positive breast cancer in the elderly: an expert consensus perspective.
Del Barco, Sonia; (...); Servitja, Sonia
Article. 10.1007/s12094-024-03838-1. 2025
Survival, quality of life (QoL) and geriatric outcomes of elderly patients (pt) with advanced non-small cell lung cancer (NSCLC), treated with pembrolizumab (P) in the first-line setting
Blanco, R; (...); Vidal, OJJ
Meeting Abstract. 10.1016/j.annonc.2020.08.1631. 2020
The SIOG COVID-19 working group recommendations on the rollout of COVID-19 vaccines among older adults with cancer.
Mislang AR; (...); Battisti NML
Letter. 10.1016/j.jgo.2021.03.003. 2021
Undertreatment and overtreatment in older patients treated with chemotherapy.
Feliu J; (...); Molina-Garrido MJ
Article. 10.1016/j.jgo.2020.10.010. 2020
Update on the management of elderly patients with colorectal cancer.
Soler-Gonzalez, Gemma; (...); Girones-Sarrio, Regina
Article. 10.1007/s12094-023-03243-0. 2023
Update on the management of older patients with pancreatic adenocarcinoma: a perspective from medical oncology.
Guillot Morales M; (...); Gironés Sarrió R
Article. 10.1007/s12094-024-03386-8. 2024
Updated SIOG COVID-19 working group recommendations on COVID-19 vaccination among older adults with cancer.
Soto-Perez-de-Celis, Enrique; (...); Battisti, Nicolo Matteo Luca
Article. 10.1016/j.jgo.2022.07.005. 2022
Use Of Iodine-131 (RAI) For The Initial Diagnosis And Treatment Of Differentiated Thyroid Cancer (DTC) In Spain And Portugal (ERUDIT Study)
Casas, JV; (...); Orcajo, L
Meeting Abstract. 2020